Image-Guided Automation Cuts Organoid Culture Hands-On Time by 22 Hours Weekly
核心洞察
The CellXpress.ai Automated Cell Culture System (搜索) reduces weekly hands-on time for dome-based patient-derived organoid culture by approximately 22 hours at a modest scale of 10 x 24 well plates.
AI-based decision-making, driven by deep-learning image segmentation, automatically triggers organoid passaging based on the presence of sufficient mature organoids, reducing operator-dependent variability.
The system integrates liquid handling, incubation, and automated imaging into one continuous workflow, enabling 24/7 operation without requiring 24/7 staffing.
Dome-based patient-derived organoid (PDO) culture remains among the most labor-intensive and operator-sensitive processes in routine laboratory use, often requiring tens of hours of manual work each week. Molecular Devices UK Ltd (搜索) has introduced the CellXpress.ai Automated Cell Culture System (搜索), an image-guided automation platform specifically engineered for dome-based organoid culture that replaces hands-on processes with completely automated protocols while preserving culture quality.
At a modest scale of 10 x 24 well plates (two plates processed simultaneously), manual dome-based tissue-derived organoid culture demands approximately 20–25 hours of hands-on work per week. The CellXpress.ai system reduces this burden dramatically, saving roughly 22 hours of hands-off operator time weekly. This time savings spans the full culture cycle, including organoid dome seeding (150 minutes saved), organoid feeding and media exchange (240 minutes saved), imaging for maintenance decisions (450 minutes saved), and organoid passaging at a 1:3 ratio (475 minutes saved).
The system addresses several persistent client challenges. Time-intensive maintenance, limited scalability constrained by expert availability, operator-dependent variability in dome handling and decision-making, and the after-hours burden of routine feeding, monitoring, and passaging outside normal work hours are all mitigated. By adopting the CellXpress.ai system, laboratories can consistently manufacture large-scale organoid cultures without increasing headcount or compromising quality.
A central feature of the platform is AI-based automated decision-making for organoid passaging. Organoids are periodically imaged using transmitted light (TL), and images are segmented by the software's deep-learning tool, SINAP, followed by analysis for a range of phenotypic measurements. Organoids are then classified into "mature" and "immature" phenotypes via AI-based classification. Passaging decisions are automatically triggered by the software based on the presence of sufficient mature organoids in culture, applying clear, image-derived decision requirements that minimize variability and dependence on user expertise.
The CellXpress.ai system supports both routine and complicated dome-based organoid processes by incorporating liquid handling, incubation, and automated imaging into one continuous workflow. This integration standardizes each stage, from seeding through to passaging, and enables 24/7 operation without 24/7 staffing. Staff presence is not required for feeding, monitoring, and passaging, which occur at a biologically appropriate rate, with decisions surrounding the analyzed cultures made according to predefined criteria rather than staff availability.
Beyond time savings, the platform delivers downstream scientific benefits. AI-based decision-making coupled with automation ensures much more consistent organoid culture, reducing assay noise and enabling more robust, reproducible assays further downstream. This allows skilled scientists to be redeployed to high-value tasks such as designing experiments or analyzing data, making laboratories more efficient and ultimately accelerating research programs.
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software, and consumables for life science research, pharmaceutical, and biotherapeutic development. Its portfolio includes platforms for high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. The company is headquartered in Silicon Valley, California, with offices around the globe.